Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.

CONCLUSIONS: The mean VA of eyes that switched treatments from ranibizumab to aflibercept was not different 12 months later. There was a modest increase in treatment intervals and a somewhat greater proportion of eyes that were graded as inactive after the switch.
PMID: 26994110 [PubMed - as supplied by publisher]

Source: The British Journal of Ophthalmology - March 18, 2016 Category: Opthalmology Authors: Barthelmes D, Campain A, Nguyen P, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, Guymer R, Essex RW, Morlet N, Gillies MC, Fight Retinal Blindness! Project Investigators Tags: Br J Ophthalmol Source Type: research